Ilomedin (Iloprost Trometamol)

Iloprost trometamol is a synthetic prostacyclin analogue that activates the IP (prostacyclin) receptor on vascular smooth‑muscle cells. This activation raises intracellular cyclic‑AMP, causing vasodilation, inhibition of platelet aggregation, and anti‑inflammatory effects, which together improve pulmonary hemodynamics and microcirculatory blood flow.

The dosing regimen for Ilomedin is individualized and set by the prescribing healthcare professional based on the patient's clinical condition, response, and tolerance. Specific infusion rates and duration are determined by the treating physician and may be adjusted during therapy.

Safety of Ilomedin in pregnancy and lactation has not been established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To order Ilomedin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and the necessary import documentation.

Ilomedin (iloprost) is a short‑acting prostacyclin analogue administered intravenously, whereas agents such as epoprostenol and treprostinil have different routes (continuous IV or subcutaneous) and half‑lives. Iloprost offers the advantage of intermittent dosing and may be preferred in settings where continuous infusion is less practical, though efficacy and safety profiles are comparable across the class.

Ilomedin should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The solution should be kept in its original container until use, and any unused portion should be discarded according to local regulations after the recommended storage period.

Ilomedin is supplied as a sterile solution for injection and is administered intravenously. The infusion is prepared according to the product’s instructions, typically using a dedicated infusion set, and delivered over a prescribed period under continuous monitoring of vital signs and hemodynamic parameters.

The most serious adverse events linked to Ilomedin include severe hypotension, significant bleeding due to platelet inhibition, pulmonary edema, and potentially life‑threatening arrhythmias. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after infusion.

Ilomedin is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation. Caution is advised in individuals with uncontrolled severe hypotension, active bleeding disorders, recent major surgery, or those receiving concurrent potent vasodilators without appropriate monitoring.